General Practitioner v Lilly (AUTH/2431/8/11): Legibility of prescribing information for Bydureon ad – no breach

📅 2011 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/2431/8/11
ComplainantGeneral practitioner
CompanyEli Lilly and Company Limited
ProductBydureon (exenatide)
MaterialAdvertisement/outsert attached to July/August 2011 edition of Practical Diabetes
IssueLegibility of prescribing information (contrast and readability)
Clause(s) consideredClause 4.1
Panel findingNo breach
Notable Panel commentsGrey text on white background “not helpful”; on the limits of acceptability for contrast; ‘max’ subscript not legible in places but understandable in context
Complaint received10 August 2011
Case completed7 September 2011
AppealNo appeal
Additional sanctionsNone stated

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • A general practitioner complained that the prescribing information on an advertisement/outsert for Bydureon (exenatide) attached to the July/August 2011 edition of Practical Diabetes was “incredibly difficult to read”.
  • The complainant alleged this contravened Clause 4.1, citing expectations for a clear style of type and that dark print on a light background is preferable.
  • Lilly responded that the prescribing information met Code requirements for height, spacing, style and legibility, and denied a breach.
  • Although denying breach, Lilly said it would change the combination of font, colour and background in future materials.
⚖️

Outcome

  • No breach of the Code was ruled.
  • The Panel considered the prescribing information was on the limits of acceptability regarding contrast (grey text on white background), but overall did not fail Clause 4.1.
  • The Panel noted Lilly’s intention to change font/colour/background in future material.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training